EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that two abstracts exploring Phase 2 Puricase® (PEG-uricase) data and quality of life in treatment-failure gout patients will be presented at the European League Against Rheumatism (EULAR) 2007 Annual Congress taking place June 13 – 16th in Barcelona, Spain. Puricase is a PEGylated recombinant porcine urate oxidase currently in Phase 3 development for patients with treatment-failure gout.
